 "USFDA approves Aurobindo Pharma owned Eugia's generic Vasopressin injection")
Aurobindo Pharma Ltd on Tuesday said its wholly-owned arm Eugia Pharma Specialties Ltd has received final approval from the US health regulator for its generic version of Vasopressin injection.
The injection is indicated to increase blood pressure in adults who suffer from sudden relaxation of blood vessels.
The approval granted by the US Food and Drug Administration (USFDA) is for manufacturing and marketing of vasopressin injection of strength 20 units/ml multiple-dose vials, Aurobindo Pharma said in a regulatory filing.
The approved product is bioequivalent and therapeutically equivalent to the reference listed drug Vasostrict injection 20 units/ml of Par Sterile Products, LLC (Par), it added.
Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shocks, such as due to post-cardiotomy or sepsis, and remain hypotensive despite fluids and catecholamines.
The product is being launched immediately, the company said.
The approved product has an estimated market size of around USD 606 million for the 12 months ending June 2022, the company said, citing IQVIA data.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app